Your browser is no longer supported. Please, upgrade your browser.
PRAN Prana Biotechnology Limited daily Stock Chart
Prana Biotechnology Limited
Index- P/E- EPS (ttm)-0.80 Insider Own18.70% Shs Outstand8.64M Perf Week4.98%
Market Cap17.80M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float1.30M Perf Month8.41%
Income-7.10M PEG- EPS next Q- Inst Own3.60% Short Float10.48% Perf Quarter21.88%
Sales0.10M P/S177.96 EPS this Y-9.70% Inst Trans- Short Ratio1.53 Perf Half Y5.63%
Book/sh0.86 P/B2.40 EPS next Y- ROA-49.90% Target Price4.00 Perf Year-0.01%
Cash/sh- P/C- EPS next 5Y- ROE-56.40% 52W Range1.09 - 2.91 Perf YTD60.91%
Dividend- P/FCF- EPS past 5Y7.60% ROI-49.90% 52W High-29.22% Beta1.07
Dividend %- Quick Ratio4.40 Sales past 5Y5.90% Gross Margin- 52W Low89.76% ATR0.17
Employees15 Current Ratio4.40 Sales Q/Q68.70% Oper. Margin- RSI (14)60.40 Volatility5.53% 10.47%
OptionableNo Debt/Eq0.00 EPS Q/Q-44.70% Profit Margin- Rel Volume0.17 Prev Close2.06
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume88.72K Price2.06
Recom- SMA206.04% SMA5017.20% SMA20011.22% Volume0 Change0.00%
Jan-05-18Initiated B. Riley FBR, Inc. Buy $4
Mar-31-14Downgrade MLV & Co Buy → Hold $11 → $3
Mar-31-14Downgrade HC Wainwright Buy → Neutral $33 → $5
Feb-18-14Initiated HC Wainwright Buy $20.50
Dec-20-12Initiated Burrill Institutional Research Mkt Outperform $5
Oct-04-11Initiated MLV Capital Buy $6
Sep-09-08Upgrade Rodman & Renshaw Mkt Perform → Mkt Outperform $8
Apr-10-19 09:02PM  Alterity Therapeutics Launches to Asian Investors Business Wire
Jan-31-19 09:01AM  Prana Receives First Orphan Drug Designation from the FDA for the Treatment of Multiple System Atrophy Business Wire +12.68%
Jan-04-19 06:50AM  Today's Research Reports on Trending Tickers: Prana Biotechnology and Gilead Sciences ACCESSWIRE
Jan-02-19 12:48PM  Why Prana Biotechnology Stock Is Skyrocketing Today InvestorPlace +50.00%
10:25AM  Prana Biotech Surges on Promised $31.4 Million Investment
09:25AM  Watch These Top Trending Stocks On Jan. 2, 2019 ACCESSWIRE
07:00AM  Life Biosciences LLC leads strategic investment of up to A$44.5 million (US$31.4 million) in Prana PR Newswire
Dec-11-18 07:16PM  Is Prana Biotechnology Limiteds (ASX:PBT) CEO Pay Justified? Simply Wall St. -7.28%
Oct-12-18 12:35AM  How Financially Strong Is Prana Biotechnology Limited (ASX:PBT)? Simply Wall St.
Oct-04-18 11:47PM  Prana Biotechnology: Pre-Clinical Evidence Demonstrates PBT434 as a Potential Treatment for MSA Business Wire
Jul-08-18 08:15PM  PBT434 Data to be Presented at the International Congress of Parkinsons Disease and Movement Disorders Business Wire
Jul-03-18 09:38PM  First Volunteers Dosed in Phase I Clinical Trial of PBT434, Pranas Lead Therapy for Parkinsonian Diseases Business Wire
Jun-13-18 08:55PM  Prana to Commence Phase 1 Clinical Trial of PBT434 for Treatment of Parkinsonian Diseases Business Wire
Oct-20-17 08:00AM  Today's Research Reports on Trending Tickers: Agenus and Prana Biotechnology ACCESSWIRE +5.85%
Jul-18-17 09:00AM  Prana Commences Research Collaboration with Takeda for the Treatment of Parkinson's Disease Gastrointestinal Neuropathology Business Wire +7.95%
Jul-05-17 09:00AM  Prana's PBT434 Lowers Alpha-Synuclein and Prevents Neurodegeneration Business Wire
08:00AM  Today's Research Reports on Stocks to Watch: Opexa Therapeutics and Prana Biotechnology Accesswire
Jun-05-17 08:30AM  Prana Appoints David Stamler as Chief Medical Officer to Lead Clinical Development Business Wire
Mar-31-17 09:30AM  Prana Biotechnology and Xenetic Biosciences Expand Their Product Promotion Accesswire -7.94%
Oct-18-16 11:00AM  New Data from Reach2HD Trial Presented at American Neurological Association Annual Meeting Business Wire
Oct-08-16 01:04PM  PRANA BIOTECHNOLOGY LTD Financials
Jul-27-16 12:22PM  Prana Alzheimer's disease data features at world leading conference Business Wire
Jun-22-16 02:54PM  Five Stocks on the Move Today Amid a Mixed Market Insider Monkey
02:54PM  Five Stocks on the Move Today Amid a Mixed Market at Insider Monkey
Apr-11-16 08:00AM  Prana Regains Compliance with NASDAQ Continued Listing Requirements Continues to Work Towards FDA Submission Other
Feb-26-16 08:00AM  Prana Biotechnology Half Year Investor Report Other
Nov-16-15 09:00AM  Prana Chief Scientific Advisor Receives Smithsonian American Ingenuity Award Business Wire
Nov-09-15 08:00AM  Prana Receives Non-Compliance Notice Regarding NASDAQ Minimum Bid Price Requirement Business Wire
Aug-27-15 08:00AM  Prana Reports FY15 Financial Results Business Wire
Jun-30-15 11:58PM  Prana Announces Safety Outcomes of Alzheimers IMAGINE Extension Trial Business Wire
Jun-01-15 09:00AM  European Commission Approves PBT2 Orphan Designation for Huntingtons Disease Business Wire
Apr-27-15 11:22PM  PBT2 Recommended for Orphan Designation in Europe Other
Mar-10-15 02:01PM  4 Stocks Under $10 to Trade for Big Breakouts
Feb-13-15 12:40PM  Broker does a 180 on Glaxo; shares surge at MarketWatch
Jan-01-15 11:52AM  The Worst-Performing Biotech Stocks Of 2014 Forbes
Nov-19-14 11:00AM  The Lancet Neurology Publishes Prana's Huntington Disease Trial Other
Oct-07-14 01:00PM  Horizon Pharma's Actimmune Gets Orphan Drug Designation Zacks
Sep-08-14 04:35PM  Prana Biotechnology Up on Orphan Drug Status for PBT2 Zacks
Sep-05-14 04:49PM  US STOCKS-S&P 500 ends at record as jobs report eases Fed worries Reuters
02:17PM  US STOCKS-Wall St rises as weak payrolls ease Fed worries Reuters
12:17PM  US STOCKS-Wall St flat following weak payrolls report Reuters
10:35AM  Huntingtons Disease Orphan Drug Designation Could Rescue Prana at 24/7 Wall St.
10:17AM  US STOCKS-Wall St little changed after weak payrolls report Reuters
09:46AM  Why Prana Biotechnology (PRAN) Stock Is Surging Today at TheStreet
09:15AM  US STOCKS-Wall St set to dip at open after payrolls report Reuters
08:00AM  US STOCKS-Futures dip before payrolls; on track for weekly fall Reuters
07:45AM  Prana receives FDA Orphan Drug Designation for PBT2 for Huntington Disease PR Newswire
Aug-29-14 07:00AM  3 Biotech Stocks Under $10 in Breakout Territory at TheStreet
Jul-17-14 04:27PM  Prana updates Alzheimer disease development program
04:10PM  Prana Alzheimer's disease Development Program update PR Newswire
02:05PM  Why Prana Biotechnology (PRAN) Stock Is Surging Today at TheStreet
Jul-11-14 06:46AM  5 Stocks Under $10 Set to Soar at TheStreet
Jun-26-14 01:56PM  5 Stocks Under $10 Setting Up to Soar at TheStreet
Jun-19-14 06:00AM  4 Stocks Under $10 to Trade for Breakouts at TheStreet
Jun-11-14 06:30AM  3 Stocks Under $10 Making Big Moves at TheStreet
May-28-14 11:33AM  Here's the Next Small-Cap Stock the Spec Money Will Chase at TheStreet
09:00AM  Prana rises 7.9% at
May-27-14 03:28PM  Prana Biotechnology (PRAN) Stock Suddenly Surges Other
May-14-14 07:30AM  World leader in movement disorders Professor Ira Shoulson joins Prana Board PR Newswire
Apr-30-14 01:26PM  Biotech and the Fallacy of Analyst Ratings at Motley Fool
Apr-23-14 09:01AM  Zeldes Haeggquist & Eck LLP Announces Investigation of Prana Biotechnology Limited Business Wire
Apr-22-14 02:05PM  A Beaten-Down Biotech Stock Poised to Perk Up at TheStreet
Apr-14-14 04:15PM  Prana Biotechnology Is Still A Short After Recent Alzheimer's Failure Other
11:16AM  Are These Three Biotech Companies Still Worth A Gamble? at Seeking Alpha
Apr-13-14 11:09AM  Nasdaq Falls Below 4,000 on Biotech, Technology Weakness at 24/7 Wall St.
Apr-08-14 09:34AM  The Worst Biotech Failures of the Week at Motley Fool
Apr-05-14 02:15PM  This Week in Biotech: Data Disappointments Come in Threes at Motley Fool
Apr-04-14 08:43AM  3 Stocks Under $10 Making Big Moves at TheStreet
07:00AM  Biotech Stock Mailbag: Celgene, IsoRay, Northwest Bio, Bubble Worries at TheStreet
Apr-01-14 02:10PM  Will Pranas Implosion Go All the Way? 24/7 Wall St.
10:13AM  Why Prana Biotechnology (PRAN) Stock Is Down Today Other
Mar-31-14 07:35PM  Big Movers Today: Panera, Delta, GM, and Prana Biotechnology at Motley Fool
07:03PM  Down 70%: Is Prana Biotechnology Ltd. a Buy? Other
03:21PM  Why Prana Biotechnology Limited Got Pummeled at Motley Fool
12:40PM  Biotech's shares fall 70% on tests at MarketWatch
12:18PM  Midday Movers: Amgen, Biogen, Priceline & More at CNBC
12:18PM  On The Fly: Midday Wrap at
10:42AM  Prana tumbles after Alzheimer's drug study does not hit endpoint at
10:37AM  J&J sells Ortho-Clinical; BlackBerry extends losses at MarketWatch
10:27AM  Wall Street Notches Slight Gains for the Month and the Quarter at New York Times
09:05AM  Stocks to Watch: Biofuel Energy, GM, Prana Biotechnology Other
09:00AM  Ahead of the Bell: Prana Biotechnology shares skid AP
08:45AM  Prana Biotech downgraded by HC Wainwright
08:20AM  Biotech Firm Prana Misses Goal on Alzheimer Drug Other
07:49AM  U.S.-listed shares of Prana sink after drug trial at MarketWatch
07:05AM  Prana Biotechnology announces preliminary results of Phase 2 IMAGINE trial of PBT2 in Alzheimer's disease PR Newswire
06:54AM  Prana Alzheimer's Study Fails at TheStreet
Mar-21-14 04:09PM  3 Biotechs Expecting Data at Motley Fool
Mar-20-14 03:49PM  Prana Biotechnology - A Gamble Worth Taking For Both Long- And Short-Term Investors at Seeking Alpha
Mar-07-14 08:38AM  Alzheimer's Research Stocks - Technical And Other Considerations at Seeking Alpha
Mar-04-14 03:24PM  Alzheimer's Dementia: Eli Lilly's Solanezumab Or Prana's PBT2, Which Would You Take? at Seeking Alpha
Mar-03-14 01:13PM  A Busy Calendar of March Biotech Events at TheStreet
09:38AM  Prana: Right Drug, Wrong Dose at Seeking Alpha
Mar-02-14 11:58AM  The Best- And Worst-Performing Biotech Stocks, Feb. 21 to Feb. 28 at Forbes
Mar-01-14 07:31AM  3 Humongous Health-Care Stocks This Week at Motley Fool
06:45AM  Bipolar Prana: PBT2 For Alzheimer's Dementia, Implications Of The Upcoming IMAGINE Trial Results Other
Feb-22-14 12:45PM  Positive Phase 2 Results For Prana Biotechnology In Huntington's Disease: Behind The Smoke And Mirrors at Seeking Alpha
Feb-21-14 09:03AM  Biotech Stock Mailbag: Raptor, Chelsea, Oncogenex, More Hate Mail! at TheStreet
07:30AM  SA PRO: Top Long And Short Ideas, Thursday February 20 at Seeking Alpha
Prana Biotechnology Limited researches and develops therapeutic drugs for the treatment of Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidates include PBT434 that is in Phase I clinical trial for the treatment for Parkinson's disease and other movement disorders; and PBT2, which has completed four Phase I studies and a Phase IIa clinical trial for patients with Alzheimer's disease. It also completed the IMAGINE Phase II biomarker imaging trial in Alzheimer's disease; and a open label IMAGINE Extension study and the Reach2HD Phase IIa trial in Huntington disease. The company was founded in 1997 and is based in Melbourne, Australia.